# Design Therapeutics Inc. (DSGN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $15.14, market value $947 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Design Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.7×**. The shares trade at 4.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -5.8%** (5-yr avg -14.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -32.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: -30.9%**. Each dollar of assets produces -30.9% of profit.

## Growth
- **EPS growth (1 yr): -38.6%**. Earnings per share fell 38.6%.

## Financial health
- **Current ratio: 17.14** (quick 17.14). Current assets cover the next year's liabilities 17.14 times.
- **Altman Z-score: 42.77**. A Z-score of 42.77 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Design Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 147.8%** (YTD 61.4%, 3-mo 42.2%). The shares are up 147.8% over twelve months including dividends.
- **From 52-week high: -12.2%** (186.7% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 1.23** (volatility 78%). Beta of 1.23 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DSGN · Page: https://foliofundamentals.com/stocks/dsgn

Not investment advice.